Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Sinopharm Group Co., Ltd.    1099   CNE100000FN7

SINOPHARM GROUP CO., LTD.

(1099)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinopharm : Venezuela approves use of China's Sinopharm coronavirus vaccine

03/01/2021 | 05:55pm EDT

CARACAS, March 1 (Reuters) - Venezuela has approved the use of China's Sinopharm vaccine against the novel coronavirus, the South American country's health ministry said on Monday, after it began administering Russia's Sputnik V vaccine last month.

The ministry did not specify how many Sinopharm doses it would acquire or when they would arrive. President Nicolas Maduro had previously said the country was in talks with China over the possible use of its vaccines.

"Thanks to the cooperation between China and Venezuela we are able to attend to the health and life of our people," the ministry wrote on Twitter.

Venezuela has said it received the first 100,000 doses of Sputnik V on Feb. 13, and has invested $200 million to buy 10 million doses in the country of some 25 million.

An advisor to opposition leader Juan Guaido - recognized by dozens of countries as Venezuela's legitimate president - said last week the country could begin receiving coronavirus vaccines via the global COVAX program in May. Maduro has not publicly confirmed that government officials have been involved in those talks.

The once-prosperous OPEC nation is experiencing a dramatic economic collapse that has left its healthcare system in a shambles.

Venezuela's National Academy of Medicine said on Monday that the country has secured enough vaccine supplies to inoculate some 38% of the population, the second-lowest level in Latin America and ahead of only El Salvador.

Official data shows Venezuela has reported 139,116 coronavirus cases and 1,344 deaths. Opposition politicians question those figures, arguing testing has been insufficient. (Reporting by Vivian Sequera in Caracas and Luc Cohen in New York; editing by Richard Pullin)


© Reuters 2021
All news about SINOPHARM GROUP CO., LTD.
04:45aSINOVAC BIOTECH  : China's COVID-19 vaccine output to hit 3 billion by year-end ..
RE
01:09aSinopharm's protein-based COVID-19 vaccine candidate gets China clinical tria..
RE
04/06Who now expects to review chinese covid-19 vaccines by sinopharm and sinovac ..
RE
04/02SINOPHARM  : China National Accord Medicines' 2020 Net Profit Rises Nearly 11%
MT
04/01Namibia gets first-ever funds from IMF to help fight COVID-19
RE
04/01SINOPHARM  : Announcement principal financial data of sinopharm accord for the y..
PU
03/30ASTRAZENECA  : Asian countries seek vaccine supplies after India export curbs hi..
RE
03/30ASTRAZENECA  : WRAPUP 1-Asian countries scramble for vaccine supplies after Indi..
RE
03/29UAE Company Gulf Pharmaceutical To Start Producing Sinopharm COVID-19 Vaccine
MT
03/29Probi and Sinopharm enter strategic partnership in China
AQ
More news
Financials
Sales 2020 459 B 70 096 M 70 096 M
Net income 2020 6 851 M 1 046 M 1 046 M
Net Debt 2020 15 485 M 2 363 M 2 363 M
P/E ratio 2020 7,46x
Yield 2020 4,00%
Capitalization 52 090 M 7 949 M 7 950 M
EV / Sales 2020 0,15x
EV / Sales 2021 0,13x
Nbr of Employees 93 764
Free-Float 43,0%
Chart SINOPHARM GROUP CO., LTD.
Duration : Period :
Sinopharm Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOPHARM GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 21,58 CNY
Last Close Price 16,71 CNY
Spread / Highest target 59,5%
Spread / Average Target 29,1%
Spread / Lowest Target 2,73%
EPS Revisions
Managers and Directors
NameTitle
Yong Liu President & Executive Director
Xiao Juan Li Chief Financial Officer
Fang Yao Chairman-Supervisory Board
Qing Ming Yu Chairman
Wu Ping Tao Member-Supervisory Board
Sector and Competitors